Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Crestone Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units, which suggests a diverse set of technical reviews for the current portfolio. This distribution indicates that each pending matter is being evaluated independently without administrative overlap.
The busiest examiner, SCHMIDT, IZABELA MARIA, is responsible for 1 busiest examiner pending action. This accounts for half of the 2 total pending actions currently being prosecuted. With 2 distinct examiners and 2 distinct art units involved, the company's prosecution efforts are fully distributed across its active matters. This structure requires the company to maintain separate strategies for each of its active cases within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 27d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 1623 | §102§103§112 | Non-Final OA | 27d | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial